133 related articles for article (PubMed ID: 16818279)
21. Phenotypic difference of normal plasma cells from mature myeloma cells.
Harada H; Kawano MM; Huang N; Harada Y; Iwato K; Tanabe O; Tanaka H; Sakai A; Asaoku H; Kuramoto A
Blood; 1993 May; 81(10):2658-63. PubMed ID: 8490175
[TBL] [Abstract][Full Text] [Related]
22. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
23. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
[TBL] [Abstract][Full Text] [Related]
24. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
Yaccoby S
Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
[TBL] [Abstract][Full Text] [Related]
25. Age related variation in expression of CD21 and CD32 on bovine lymphocytes: a cross-sectional study.
Chattha KS; Firth MA; Hodgins DC; Shewen PE
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):70-8. PubMed ID: 19243842
[TBL] [Abstract][Full Text] [Related]
26. In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas.
Troadec S; Chentouf M; Cérutti M; Nguyen B; Olive D; Bès C; Chardès T
J Immunother; 2007; 30(2):190-202. PubMed ID: 17471166
[TBL] [Abstract][Full Text] [Related]
27. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow.
Iqbal MS; Otsuyama K; Shamsasenjan K; Asaoku H; Mahmoud MS; Gondo T; Kawano MM
Eur J Haematol; 2009 Oct; 83(4):302-12. PubMed ID: 19500134
[TBL] [Abstract][Full Text] [Related]
28. Antibody therapy for treatment of multiple myeloma.
Maloney DG; Donovan K; Hamblin TJ
Semin Hematol; 1999 Jan; 36(1 Suppl 3):30-3. PubMed ID: 9989487
[TBL] [Abstract][Full Text] [Related]
29. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells.
Huang N; Kawano MM; Mahmoud MS; Mihara K; Tsujimoto T; Niwa O; Kuramoto A
Blood; 1995 Jun; 85(12):3704-12. PubMed ID: 7780154
[TBL] [Abstract][Full Text] [Related]
30. A regulatory role for Fcgamma receptors CD16 and CD32 in the development of murine B cells.
de Andres B; Mueller AL; Verbeek S; Sandor M; Lynch RG
Blood; 1998 Oct; 92(8):2823-9. PubMed ID: 9763567
[TBL] [Abstract][Full Text] [Related]
31. A new phenotypic classification of bone marrow plasmacytosis.
Kawano MM; Mihara K; Tsujimoto T; Huang N; Kuramoto A
Int J Hematol; 1995 Jun; 61(4):179-88. PubMed ID: 8547606
[TBL] [Abstract][Full Text] [Related]
32. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
[TBL] [Abstract][Full Text] [Related]
33. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage.
Yamashita T; Tamura H; Satoh C; Shinya E; Takahashi H; Chen L; Kondo A; Tsuji T; Dan K; Ogata K
Clin Cancer Res; 2009 Feb; 15(3):770-7. PubMed ID: 19188146
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
35. Characterization of antigen-presenting cells in human apical periodontitis lesions by flow cytometry and immunocytochemistry.
Lukić A; Vasilijić S; Majstorović I; Vucević D; Mojsilović S; Gazivoda D; Danilović V; Petrović R; Colić M
Int Endod J; 2006 Aug; 39(8):626-36. PubMed ID: 16872457
[TBL] [Abstract][Full Text] [Related]
36. [Myeloma precursor cells and their differentiation].
Kawano MM
Nihon Rinsho; 1995 Mar; 53(3):552-6. PubMed ID: 7699884
[TBL] [Abstract][Full Text] [Related]
37. Characterization of in vitro growth of multiple myeloma cells.
Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of Pax-5 gene in human myeloma cells.
Mahmoud MS; Huang N; Nobuyoshi M; Lisukov IA; Tanaka H; Kawano MM
Blood; 1996 May; 87(10):4311-5. PubMed ID: 8639790
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma.
Seegmiller AC; Xu Y; McKenna RW; Karandikar NJ
Am J Clin Pathol; 2007 Feb; 127(2):176-81. PubMed ID: 17210522
[TBL] [Abstract][Full Text] [Related]
40. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
